In part 7, the conclusion of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the Watson tools available and how to access them.
Lisa Latts MD, MSPH, MBA, FACP is Deputy Chief Health Officer for IBM Watson Health.
Transcript of this video segment:
Freed: The science, Sugar.IQ, because that use is limited, where can family practitioners and nurse practitioners find out what’s available that they can use today, how would they go about finding out what’s available and how they can access it?
Latts: So, in Watson we’ve got lots of areas of diabetes that we’re working on currently. For a family physician coming to things like the ADA may be possible but I think getting information from aggregate sources that put it together in a way and show them the highlights and the important things that they need to know for their practice, right now is where we’re at. But in the future, I think there will be more and more tools that help surface these insights that will help individuals make better decisions based on their individual patient characteristics.
Freed: So, what’s available now that they could possibly use in their office practice?
Latts: So, there are definitely tools out there that help you find sort of summary information. For example, we’ve got a tool that we use within IBM Watson Health called Micromedex that helps surface the best information from a pharmaceutical perspective, looking at different drugs and how they might be used and helping you figure out how to use those drugs in the most appropriate way. And so, there’s tools like that that you can access to and then help you at the point of care get the best information you can today.
Freed: So, for my final question, if this is viewed by pharmacists, family practitioners, nurse practitioners, dietitians, what’s the takeaway message?
Latts: So, I think the takeaway message is that what’s coming is the ability to have at the point of care better insights and more information to help you help your patients make diabetes care easier. So, it’s coming. We’re right on the cusp of that. We’re learning so much about diabetes. You just look at the size of this meeting at the ADA that we’re at, which is enormous. I heard yesterday that 60% of the presenters here are non-US based, so it’s not just the innovations that’s coming out of the United States, it’s worldwide innovation in diabetes. And so, there’s so much changing and so much more than we know now than we knew a year ago, much less 10 or 20 years ago So, it’s incredible changes are coming and you have many more options today than you have yesterday. So, being able to understand these things and get the best information you can for your patients will help your patients have better outcomes.